Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208532 | 0.80 | ELANE (0.53) | ELANEHPGDROCK2KMT2AGPR119 | |
| SCHEMBL12510895 | 0.80 | ELANE (0.53) | ELANEHPGDGPR119STAT3 | |
| SCHEMBL2207579 | 0.79 | ELANE (0.52) | ELANEHPGDKMT2AGPR119STAT3 | |
| SCHEMBL13875110 | 0.76 | ROCK2 (0.33) | ELANEROCK2GPR119 | |
| SCHEMBL13513386 | 0.72 | SMN1; SMN2 (0.37) | HPGDKMT2A | |
| SCHEMBL27832904 | 0.71 | — | — | |
| SCHEMBL13955359 | 0.70 | — | — | |
| SCHEMBL16373419 | 0.70 | ELANE (0.52) | ELANEHPGDROCK2KMT2ASTAT3 | |
| SCHEMBL14977321 | 0.68 | DHODH (0.62) | KMT2A | |
| SCHEMBL14977320 | 0.68 | LMNA (0.44) | ELANEKMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| CN-101426783-B | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2013-10-30 | — | — | CN | disclosed |
| US-7981918-B2 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981918-B2 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| CN-101426783-A | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-05-06 | — | — | CN | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | ELANE 1512/4885HPGD 53/4885ROCK2 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.